The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

Abstract : Met is the receptor of hepatocyte growth factor (HGF), a cytoprotective cytokine. Disturbing the equilibrium between Met and its ligand may lead to inappropriate cell survival, accumulation of genetic abnormalities and eventually, malignancy. Abnormal activation of the HGF/Met axis is established in solid tumours and in chronic haematological malignancies, including myeloma, acute myeloid leukaemia, chronic myelogenous leukaemia (CML), and myeloproliferative neoplasms (MPNs). The molecular mechanisms potentially responsible for the abnormal activation of HGF/Met pathways are described and discussed. Importantly, inCML and in MPNs, the production of HGF is independent of Bcr-Abl and JAK2V617F, the main molecular markers of these diseases. In vitro studies showed that blocking HGF/Met function with neutralizing antibodies or Met inhibitors significantly impairs the growth of JAK2V617F-mutated cells. With personalised medicine and curative treatment in view, blocking activation of HGF/Met could be a useful addition in the treatment of CML and MPNs for those patients with high HGF/MET expression not OPEN ACCESS Cancers 2014, 6 1632 controlled by current treatments (Bcr-Abl inhibitors in CML; phlebotomy, hydroxurea, JAK inhibitors in MPNs).
Type de document :
Article dans une revue
Cancers, MDPI, 2014, 6, pp.1631 - 1669. 〈10.3390/cancers6031631〉
Liste complète des métadonnées

Littérature citée [183 références]  Voir  Masquer  Télécharger
Contributeur : Elizabeth Bernardo <>
Soumis le : mercredi 23 novembre 2016 - 15:59:21
Dernière modification le : jeudi 7 février 2019 - 14:25:40
Document(s) archivé(s) le : mardi 21 mars 2017 - 03:56:40


Fichiers éditeurs autorisés sur une archive ouverte




Marjorie Boissinot, Mathias Vilaine, Sylvie Hermouet. The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?. Cancers, MDPI, 2014, 6, pp.1631 - 1669. 〈10.3390/cancers6031631〉. 〈inserm-01401601〉



Consultations de la notice


Téléchargements de fichiers